Manner Carrie Eglinton Purchases 32,300 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton bought 32,300 shares of the firm’s stock in a transaction on Friday, March 20th. The stock was acquired at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief executive officer directly owned 2,190,874 shares in the company, valued at approximately $6,419,260.82. The trade was a 1.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Manner Carrie Eglinton also recently made the following trade(s):

• On Friday, March 13th, Manner Carrie Eglinton purchased 22,022 shares of OraSure Technologies stock. The shares were acquired at an average price of $3.00 per share, with a total value of $66,066.00.

OraSure Technologies Trading Down 0.6%

Shares of NASDAQ OSUR opened at $3.06 on Wednesday. OraSure Technologies, Inc. has a 12 month low of $2.08 and a 12 month high of $3.82. The firm has a market capitalization of $211.54 million, a price-to-earnings ratio of -3.29 and a beta of 0.88. The business has a 50-day moving average of $2.87 and a 200-day moving average of $2.78.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%.The company had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. On average, analysts predict that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $3.00.

Hedge Funds Weigh In On OraSure Technologies

Large investors have recently added to or reduced their stakes in the business. Quadrature Capital Ltd purchased a new position in OraSure Technologies in the 4th quarter worth $28,000. Prudential Financial Inc. purchased a new stake in OraSure Technologies during the second quarter valued at about $31,000. L2 Asset Management LLC bought a new position in shares of OraSure Technologies during the second quarter valued at about $39,000. Coldstream Capital Management Inc. increased its holdings in shares of OraSure Technologies by 128.2% in the second quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 7,477 shares during the period. Finally, Amundi bought a new stake in shares of OraSure Technologies in the 1st quarter valued at about $47,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.